Taiho's late-stage Duchenne candidate fails trial

Taiho's late-stage Duchenne candidate fails trial

Taiho has suffered a blow to its near-term pipeline after a drug candidate for Duchenne muscular dystrophy (DMD) missed the mark in a phase 3 trial

A program for youth leaders leaves me optimistic for the future

A couple weeks ago, I had the privilege of participating in a unique event designed for higher education students here in Singapore. It’s offered by Youth Corps Singapore to foster a sense of service among the next generation of leaders. As one of three ambassadors representing the Muscular Dystrophy Association (Singapore), I shared my experiences as a Duchenne muscular dystrophy (DMD) advocate to foster understanding and empathy in these young…

Otsuka’s Taiho reports Phase 3 fail for Duchenne muscular dystrophy drug

An Otsuka subsidiary said Tuesday that its experimental therapy for Duchenne muscular dystrophy has failed its Phase 3 primary endpoint in a group of ambulatory patients in Japan. Taiho Pharmaceutical

Taiho’s DMD therapy misses the mark in Phase III trial

Taiho Pharmaceutical’s investigational Duchenne muscular dystrophy (DMD) therapy, pizuglanstat, has shown no benefit in a Phase III trial.The post Taiho’s DMD therapy misses the mark in Phase III trial appeared first on Clinical Trials Arena.